How fast do weight loss injections work?

What the trial data says about the first weeks

The clearest picture comes from the large phase-3 programmes. In SURMOUNT-1, published in the New England Journal of Medicine, adults taking tirzepatide (Mounjaro) achieved average body-weight reductions of around 20–21% at the highest dose over 72 weeks. In STEP 1, the equivalent trial for semaglutide 2.4mg (Wegovy), the average reduction was around 15% over 68 weeks. Both trials enrolled thousands of adults alongside a reduced-calorie diet and increased physical activity.

Neither trial reported dramatic losses in week one. The earliest noticeable changes are physiological rather than on-the-scales: a reduced desire to eat large portions, food feeling more satisfying sooner, and (for many participants) a quietening of what researchers sometimes call persistent food noise. These shifts can appear within the first injection or two. Body weight, though, responds more slowly. Early weeks often bring a modest drop as appetite falls and calorie intake adjusts; the steeper trajectory tends to follow as the dose is increased by the prescriber over subsequent months.

A question our prescribers hear most weeks is some version of "it's been two weeks and I've only lost a couple of pounds — is something wrong?" If you are wondering the same thing, our page on how fast weight loss injections actually work walks through what the evidence says about realistic timelines at each stage. Two weeks at the starter dose is the system settling in, not the treatment failing.

Why the dose schedule shapes the speed of results

Both Mounjaro and Wegovy begin at doses designed primarily for tolerability, not for maximum effect. Tirzepatide starts at 2.5mg and is typically stepped up in four-week intervals; the first pen's job is to let the body adjust, keeping nausea and other gastrointestinal side effects manageable. Semaglutide follows a similar ladder up to its maintenance dose. The practical consequence is that the therapeutic effect is relatively modest at first and grows as the dose increases over the months that follow.

This is worth understanding before starting, because the early experience can feel underwhelming compared with the trial headlines. Those headlines represent the full duration at maintenance doses, not weeks three and four. People who stop early because results feel slow are, in effect, stepping off a programme before it has reached its most productive phase. That is partly why clinical oversight matters throughout: a prescriber can confirm whether the pace is within the expected range and whether any adjustment is warranted.

If you are weighing up the options between the two medicines, our overview of weight loss injections covers how the two licensed treatments compare on mechanism and results.

What affects individual speed of response

Trial averages describe populations, not individuals. Several factors influence how quickly someone personally sees results from a weight loss injection.

Starting weight plays a role: people with a higher BMI tend to see larger absolute losses in the early months, though percentage reductions are what the trials report. Adherence to dietary changes alongside the injection is material, GLP-1 medicines reduce appetite, but the calorie deficit still does the work; eating around the medicine's effects (choosing calorie-dense foods simply because portions feel smaller) blunts results. Physical activity, particularly anything that preserves muscle mass, affects both the pace and the composition of weight lost.

Gut transit speed varies between people and influences how the medicine is absorbed and how prominently side effects land. Metabolic history matters too: people who have dieted repeatedly may have slower initial responses due to adaptive metabolic changes. None of this is a reason to avoid treatment; it is a reason to have realistic expectations and ongoing support. Our guide to which injections are associated with faster weight loss puts these individual variables into context and explains what the data shows about accelerating progress safely.

The mechanism behind how these injections work explains the GIP and GLP-1 receptor pathways in more detail, which gives useful context for why the appetite effect often precedes the weight loss on the scales.

On the cost side, if you are comparing what different providers include in their pricing, our weight loss injection cost guide covers what a legitimate private prescription should include beyond the medicine itself.

Practical expectations: a realistic month-by-month picture

There is no single answer, but a broad pattern emerges from the trial data and from NHS guidance on tirzepatide. Weeks one to four: appetite changes are noticeable; modest weight reduction begins as intake falls. Months two to three: the dose is typically being increased; weight loss tends to accelerate. Months four to six: many people reach a dose where results become more consistent and visible. Beyond six months: losses continue, usually more gradually, as the body approaches a new equilibrium.

The full effect requires the full duration. Stopping at three months because progress has slowed is not the same as the treatment not working; weight loss at that point is often still ongoing, just less dramatic than the early weeks. NICE guidance for both Mounjaro and Wegovy includes a review point at six months on the highest tolerated dose to assess whether treatment should continue, reflecting the expectation that progress is evaluated over that timeframe.

For anyone considering starting, understanding what to expect at each stage makes the experience far less discouraging. Our guide to how long weight loss injections take to work goes into more granular detail about the longer-term trajectory. When you are ready to find out whether you are eligible and which option suits your situation, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, never software.